Analyzing ELF Test for Early Detection of Fatty Liver in High-Risk Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze enhanced liver fibrosis (ELF) scores in a high-risk population for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The study focuses on patients with metabolic syndrome and other risk factors, comparing ELF scores with traditional fibrosis assessment methods. It will also evaluate the impact of lifestyle changes and pharmacotherapy on ELF scores over time. The goal is to provide a non-invasive and cost-effective means of detecting liver fibrosis and predicting liver-related events in primary care settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: ≥ 18 years
* NAFLD/NASH and non-NAFLD/NASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023.

Exclusion Criteria:

* Patients with incomplete data and those lost to follow up.

Where it's running

• Methodist Dallas Medical Center
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Parvez Mantry, MD — Methodist Midlothian Medical Center
• Study coordinator: Crystee Cooper
• Email: crysteecooper@mhd.com
• Phone: 2149471280

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Peanut intake and liver health in adults with MASLD

  This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT07646197

• Photon-counting CT and ultrasound for detecting liver fat and scarring

  This will test whether a new photon-counting CT plus ultrasound can find liver fat and scarring in adults with fatty liver or liver fibrosis, using MRI as the reference.

  Recruiting Duke University · Durham, North Carolina · NCT07495332

• Erdosteine for nonalcoholic fatty liver disease

  This trial will try erdosteine alongside standard therapy in adults with nonalcoholic fatty liver disease confirmed by ultrasound to see if it improves liver fat and liver health.

  Recruiting Phase 1/2 Tanta University · Tanta · NCT07242222

• Cilostazol for nonalcoholic fatty liver disease.

  This trial will test whether the medicine cilostazol can reduce liver fat and improve liver health in adults with nonalcoholic fatty liver disease.

  Recruiting Phase 1/2 Tanta University · Damietta, New Damietta · NCT07238985

• Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver

  This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.

  Recruiting Phenomen Pharma · Tyumen, Tyumen Oblast · NCT07068191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.